Skip to main content
BRNS
NASDAQ Life Sciences

Shareholders Approve Reverse Merger with Clywedog Therapeutics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.643
Mkt Cap
$28.063M
52W Low
$0.512
52W High
$2.92
52W Position info
26% above low
Off High info
78% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

BRNS sits 26% above its 52-week low of $0.512 on elevated volume (2.0× avg).

Summary

Barinthus Biotherapeutics shareholders have approved the reverse merger with Clywedog Therapeutics, clearing a major hurdle for the strategic transaction.


Key Events · M&A and Partnerships · BRNS

  • Merger Approved by Shareholders

    Shareholders voted overwhelmingly in favor of the Scheme of Arrangement and Scheme Implementation Proposal, with 99.98% approval at both the Court and General Meetings held on May 20, 2026.

  • Critical Step for Clywedog Merger

    This approval is a key milestone in finalizing the reverse merger with Clywedog Therapeutics, as detailed in previous filings, including the DEFM14A on April 30, 2026.

  • Addresses Prior Challenges

    The successful vote provides a path forward for the company, which recently faced a Nasdaq delisting notice and reported significant net losses in its 2025 10-K.


Analysis · BRNS · Life Sciences

Shareholders of Barinthus Biotherapeutics have overwhelmingly approved the Scheme of Arrangement and Scheme Implementation Proposal, which are critical steps to finalize the previously announced reverse merger with Clywedog Therapeutics. This approval removes a significant contingency for the merger, providing a clearer path forward for the company, especially in light of its recent Nasdaq delisting notice and financial challenges.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BRNS was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1M. The 52-week trading range was $0.51 to $2.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRNS - Latest Insights

BRNS
Sep 01, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.765
Real-time Price: $0.800 info
Change: +$0.035 (+5%) info
Market Cap: $30.232M info
BRNS
Aug 25, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.603
Real-time Price: $0.800 info
Change: +$0.197 (+33%) info
Market Cap: $30.232M info
BRNS
Aug 06, 2026, 8:49 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5705
Real-time Price: $0.800 info
Change: +$0.2295 (+40%) info
Market Cap: $30.232M info
BRNS
Aug 06, 2026, 8:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.800 info
Change: +$0.210 (+36%) info
Market Cap: $30.232M info
BRNS
Jul 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6201
Real-time Price: $0.800 info
Change: +$0.1799 (+29%) info
Market Cap: $30.232M info